PODXL and neoplasm: The results of a subsequent study indicate that the tumor specificity of POD0447 results from its ability to bind to the Thomsen-Friedenreich (TF) antigen (Galβ1-3GalNAcα1-Ser/Thr), a well-studied TACA [5] expressed on a podocalyxin backbone.